18:33 , Dec 14, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
17:50 , Dec 7, 2018 |  BC Extra  |  Company News

Millendo, OvaScience merge, raise $50M

Emerging from the reverse-merger of private endocrine company Millendo Therapeutics Inc. and former public fertility company OvaScience Inc., Millendo Therapeutics Inc. (NASDAQ:MLND) raised $49.5 million in a financing Friday. The combined company will begin trading...
18:26 , Nov 30, 2018 |  BC Week In Review  |  Clinical News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

EMA's CHMP recommended a basket of approvals and label extensions on Nov. 16, including the first all-oral treatment for African trypanosomiasis (sleeping sickness). The agency issued no negative opinions in its monthly roundup. The agency...
22:19 , Nov 16, 2018 |  BC Extra  |  Company News

CHMP backs first all-oral sleeping sickness treatment, extensions for Blincyto, Opdivo-Yervoy combo

EMA's CHMP recommended a basket of approvals and label extensions on Friday, including the first all-oral treatment for African trypanosomiasis (sleeping sickness). The agency issued no negative opinions in its monthly roundup. The agency backed...
19:51 , Nov 2, 2018 |  BC Week In Review  |  Company News

Strongbridge hands off Macrilen to Novo for sizable return

Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), netting a 6x return. FDA approved...
20:56 , Oct 31, 2018 |  BC Extra  |  Company News

Strongbridge hands off Macrilen to Novo for sizable return

Less than a year after acquiring U.S. and Canadian rights to Macrilen macimorelin acetate, Strongbridge Biopharma plc (NASDAQ:SBBP) handed those rights off to Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), netting a 6x return. FDA approved...
06:12 , Aug 10, 2018 |  BC Week In Review  |  Company News

Millendo, OvaScience reverse merging

Fertility company OvaScience Inc. (NASDAQ:OVAS) will reverse-merge with endocrine play Millendo Therapeutics Inc. (Ann Arbor, Mich.) in an all-stock deal. The resulting company will focus on developing Millendo's pipeline for orphan indications. New Enterprise Associates,...
18:42 , Dec 22, 2017 |  BC Week In Review  |  Company News

Millendo to acquire Alize, gains Prader-Willi candidate

Millendo Therapeutics Inc. (Ann Arbor, Mich.) acquired Alizé Pharma S.A.S. (Lyon, France), an Alizé Pharma (Lyon, France) company, in a stock deal. Financial terms were not disclosed. The former Alizé Pharma S.A.S. facilities will maintain...
15:01 , Dec 22, 2017 |  BC Week In Review  |  Clinical News

FDA approves Aeterna's Macrilen

FDA approved a resubmitted NDA for Macrilen macimorelin acetate (Macrimorelin-GHST, AEZS-130) from Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna plans to launch the oral ghrelin-mimetic growth hormone...
20:17 , Dec 21, 2017 |  BC Extra  |  Company News

Aeterna jumps on Macrilen approval

Aeterna Zentaris Inc. (TSX:AEZS; NASDAQ:AEZS) shares climbed Thursday after FDA approved a resubmitted NDA for Macrilen macimorelin acetate for use in diagnosing adult growth hormone deficiency (AGHD). Aeterna added C$0.91 (35%) to C$3.48 in Toronto,...